$MGX News
Last published 19h ago
- 19h agoMGXMetagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference in LondonGlobeNewswireEMERYVILLE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the Jefferies ...
- 1d agoMGXMetagenomi Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1d agoMGXMetagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial ResultsGlobeNewswireFDA clearance enables initiation of a first-in-human Phase 1/2 trial of MGX-001 in patients with hemophilia A
- 1w agoMGXMetagenomi Therapeutics to Present Preclinical Data Supporting MGX-001, a Potential One-Time Therapy for Hemophilia A, in Oral Presentation at 68th American Society of Hematology Annual MeetingGlobeNewswireMGX-001 data establish preclinical proof-of-concept in hemophilia AOn track to initiate global clinical trial in 2027 EMERYVILLE, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX)
- 4w agoMGXMetagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare ConferenceGlobeNewswireEMERYVILLE, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create
- 2mo agoMGXMetagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare ConferenceGlobeNewswireEMERYVILLE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create
- 3mo agoMGXMetagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial ResultsGlobeNewswireRemains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A $120.7 million in cash, cash equivalents, and
- 3mo agoMGXCLLSProlynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease PortfolioGlobeNewswireEMERYVILLE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Prolynx, a biotechnology company developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions, today
- 5mo agoMGXMetagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare ConferenceGlobeNewswireEMERYVILLE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic
- 6mo agoMGXMetagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial ResultsGlobeNewswireOn track for regulatory submission of MGX-001 to advance global clinical program, including investigational new drug application ("IND") in 4Q 2026 Publication in Nature Structural & Molecular Biology highlights
- 6mo agoMGXMetagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing EfficiencyGlobeNewswireEMERYVILLE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative
- 8mo agoMGXMetagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial ResultsGlobeNewswireCompleted pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for global regulatory submission including investigational new drug
- 8mo agoMGXMetagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare ConferenceGlobeNewswireEMERYVILLE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative
- 10mo agoMGXMetagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate OutlookGlobeNewswireNew name reflects the Company's strategic evolution focused on later-stage preclinical assets leveraging its most advanced, signature gene-editing capabilities Pre-IND meeting held in 4Q 2025 following MGX-001
- 11mo agoMGXMetagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature ConferenceGlobeNewswireEMERYVILLE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines
- 11mo agoMGXMetagenomi to Present at Jefferies Global Healthcare Conference in LondonGlobeNewswireEMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines
- 1y agoMGXMetagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership UpdatesGlobeNewswireNew MGX-001 preclinical data supports advancement into clinical development; Demonstrated curative FVIII activity in non-human primates Prioritized later-stage preclinical pipeline including wholly-owned MGX-001
- 1y agoMGXMetagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical DevelopmentGlobeNewswireMGX-001 demonstrated curative FVIII activity in non-human primates Pre-IND regulatory meeting expected in Q4 2025 with investigational new drug (IND) and clinical trial application (CTA) submissions expected in 4Q 2026
- 1y agoMGXMetagenomi Reports Business Updates and Second Quarter 2025 Financial ResultsGlobeNewswirePresented three abstracts at American Society of Gene & Cell Therapy ("ASGCT") demonstrating early proof-of-concept data across multiple gene editing technologies Well capitalized with $205.0 million in cash, cash
- 1y agoKALVMGXMetagenomi Appoints Laurence Reid, PhD to its Board of DirectorsGlobeNewswireEMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX) (the "Company"), a precision genetic medicines company committed to developing curative therapeutics for patients using its
- 1y agoMGXMetagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025GlobeNewswire- Potential best-in-class extrahepatic in vivo gene editing with all-in-one delivery to the central nervous system (CNS) is a critical milestone for the treatment of neurological disorders - - Advancements demonstrate
- 1y agoMGXMetagenomi Reports Business Updates and First Quarter 2025 Financial ResultsGlobeNewswire- Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through approximately 19 months with an encouraging safety profile - Well
- 1y agoMGXMetagenomi to Present at Upcoming Scientific MeetingsGlobeNewswireEMERYVILLE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing
- 1y agoMGXMetagenomi Reports Business Updates and Full Year 2024 Financial ResultsGlobeNewswireHemophilia A presentation at American Society of Hematology (ASH) 66th Annual Meeting demonstrated sustained Factor VIII (FVIII) activity in nonhuman primate (NHP) study for more than 16 months
- 1y agoMGXMetagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) SystemsGlobeNewswireAchieved targeted integration of a large, therapeutically relevant gene into the genome of human cells with compact CAST system AI-driven metagenomics platform facilitated discovery of CAST system with activity in human
- 1y agoMGXMetagenomi to Present at TD Cowen's 45th Annual Health Care ConferenceGlobeNewswireEMERYVILLE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing
- 1y agoCBUSCLLSMGXCLXTTotus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial OfficerGlobeNewswireEMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the
- 1y agoMGXMetagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated MilestonesGlobeNewswireMGX-001 in Hemophilia A Advances Towards US and Ex-US Regulatory Interactions in 2025 NHP Proof-of-Concept Anticipated for Secreted Protein Deficiency Platform in 2025 Leveraging MGX-001 Editing ApproachOn Track for
- 1y agoMGXMetagenomi Announces New Appointment to its Board of DirectorsGlobeNewswireEMERYVILLE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing
- 1y agoMGXMetagenomi to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireEMERYVILLE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing
- 1y agoMGXMetagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference "RNA at the Bench and Bedside IV"GlobeNewswireMGX-001, utilizing a highly specific and efficient MG29-1 nuclease, exhibits no identifiable off-target editing MG29-1 nuclease targeting the albumin safe harbor locus showed no evidence of translocations in primary
- 1y agoMGXMetagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual MeetingGlobeNewswireTherapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman primate (NHP) study through more than sixteen months of follow up MGX-001 bioengineered FVIII construct exhibited higher
- 1y agoMGXFINAL DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MetagenomiBusiness WireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Metagenomi To Contact Him Directly To Discuss Their Options If you suffered
- 1y agoMGXShareholders of Metagenomi, Inc. Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights – MGXGlobeNewswireNEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ:MGX). Shareholders who purchased shares of MGX during the class period listed are
- 1y agoMGXINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MetagenomiPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Metagenomi, Inc. ("Metagenomi" or the...
- 1y agoMGXMetagenomi Reports Business Updates and Third Quarter 2024 Financial ResultsGlobeNewswireInitiating IND-enabling activities for MGX-001 development candidate (DC) in hemophilia A; Achieved durable Factor VIII activity levels over twelve months in nonhuman primate (NHP) study On track for one to two DC
- 1y agoMGXShareholders of Metagenomi, Inc. Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights – MGXGlobeNewswireNEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ:MGX). Shareholders who purchased shares of MGX during the class period listed are
- 2y agoMGXINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MetagenomiPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Metagenomi, Inc. ("Metagenomi" or the...
- 2y agoMGXMetagenomi To Present New Preclinical Hemophilia A Data at American Society of Hematology (ASH) 66th Annual MeetingGlobeNewswireEMERYVILLE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing
- 2y agoMGXMetagenomi, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights - MGXPR NewswireThe Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the ...
- 2y agoMGXMetagenomi, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights - MGXPR NewswireThe Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the ...
- 2y agoMGXINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MetagenomiGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Metagenomi To Contact Him Directly To Discuss Their Options If you suffered losses
- 2y agoMGXMetagenomi Presents Novel, Highly Specific and Efficient Adenine Base Editors for Broad Genome Editing at ESGCTGlobeNewswireMetagenomi Adenine Base Editors (ABEs) demonstrated over 95% genome targetability Simultaneous ABE triplex editing resulted in over 95% protein knockdown in primary T-cells ABE demonstrated highly specific on-target
- 2y agoMGXThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 25, 2024 in Metagenomi, Inc. Lawsuit – MGXGlobeNewswireNEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ:MGX). Shareholders who purchased shares of MGX during the class period listed are
- 2y agoMGXINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MetagenomiPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Metagenomi, Inc. ("Metagenomi" or the...
- 2y agoMGXMetagenomi, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights - MGXPR NewswireThe Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the ...
- 2y agoMGXMetagenomi Presents Compact SMART Editing Platform at AIChE 7th International Conference on CRISPR TechnologiesGlobeNewswirePoster presentation highlights SMART adenine base editors (ABEs)small enough to be packaged into a single adeno-associated virus (AAV) Data demonstrate compact SMART system optimizations allowing
- 2y agoMGXThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 25, 2024 in Metagenomi Lawsuit - MGXPR NewswireThe Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the ...
- 2y agoMGXShareholders of Metagenomi, Inc. Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights - MGXPR NewswireThe Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the ...
- 2y agoMGXMetagenomi to Present at Chardan's 8th Annual Genetic Medicines ConferenceGlobeNewswireEMERYVILLE, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing